In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implications of HER2+ breast cancer treatment in the era of biosimilars, clinical pathways, and precision medicine.
Adam Brufsky, MD, PhD, and Sreejata Raychaudhuri, MD, recently discussed how the novel HER2+ therapies fit into breast cancer treatment.
The FDA has expanded approval for a breast cancer drug in combination with an aromatase inhibitor.
Research presented at the 2017 San Antonio Breast Cancer Symposium found that breast cancer screening was associated with a reduction in a number of surgical and treatment procedures associated with breast cancer treatment.
The US FDA has approved a therapy to treat adults with advanced, metastatic breast cancer that has progressed on endocrine therapy.